Related Experiment Video

Updated: Jun 11, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Drug resistance in mutant FLT3-positive AML

E Weisberg1, M Sattler, A Ray

  • 1Department of Medical Oncology/Hematologic Neoplasia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Ellen_Weisberg@dfci.harvard.edu

Oncogene
|July 13, 2010
PubMed

Insights

Mutant Fms-Like Tyrosine kinase-3 (FLT3) inhibitors show promise for acute myeloid leukemia (AML) therapy, but resistance is a growing concern. This study explores FLT3

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Mutant Fms-Like Tyrosine kinase-3 (FLT3) is a therapeutic target in a subset of acute myeloid leukemia (AML) patients.
  • FLT3 inhibitors are in clinical trials for AML, showing efficacy but also leading to resistance.
  • Understanding FLT3's role and resistance mechanisms is crucial for effective AML treatment.

Purpose of the Study:

  • To review the role of mutant FLT3 in AML.
  • To summarize FLT3 inhibitors in clinical and preclinical development.
  • To discuss resistance mechanisms and strategies to overcome them.

Main Methods:

  • Literature review of FLT3 inhibitors and AML resistance.
  • Analysis of preclinical and clinical data on FLT3-targeted therapies.
  • Synthesis of information on resistance pathways and potential combination therapies.

Main Results:

  • FLT3 mutations are key drivers in a significant AML subpopulation.
  • Several FLT3 inhibitors demonstrate therapeutic potential but face challenges with resistance.
  • Diverse mechanisms contribute to FLT3 inhibitor resistance in AML.

Conclusions:

  • FLT3 inhibitors are a promising avenue for AML treatment, necessitating strategies to combat resistance.
  • Further research into overcoming resistance is vital for improving patient outcomes.
  • Combination therapies may offer a path forward to enhance FLT3 inhibitor efficacy in AML.

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...